Quviviq Drug Classification
Quviviq (daridorexant) is an orexin receptor antagonist, specifically a dual orexin receptor antagonist (DORA), classified as a Schedule IV controlled substance. 1
Mechanism of Action
Daridorexant works by blocking both OX1R and OX2R orexin receptors (Ki = 0.47 and 0.93 nM, respectively). The orexin neuropeptide signaling system promotes wakefulness, and by antagonizing these receptors, daridorexant suppresses the wake drive, thereby facilitating sleep 1. This represents a fundamentally different mechanism compared to traditional sedative-hypnotics like benzodiazepines or Z-drugs, which enhance GABA activity.
Regulatory Classification
- DEA Schedule: Schedule IV controlled substance 1
- FDA Indication: Treatment of insomnia disorder characterized by difficulty falling asleep and/or maintaining sleep 1
- Available doses: 25 mg and 50 mg oral tablets 1
Clinical Context
Daridorexant is one of the newer orexin receptor antagonists approved since the 2017 AASM guidelines on pharmacological treatment of chronic insomnia 2. It joins other dual orexin receptor antagonists like suvorexant and lemborexant in this drug class 2. The medication has been studied for up to 12 months in clinical trials with 1232 subjects, showing no reports indicative of abuse liability during that period 1.
Abuse Potential
While classified as Schedule IV, daridorexant demonstrated lower "drug liking" ratings than zolpidem and suvorexant at the therapeutic 50 mg dose in recreational drug users. However, at supratherapeutic doses (100-150 mg), it showed similar abuse potential to these comparators 1. The drug does not produce physical dependence or withdrawal symptoms upon discontinuation 1.